Skip to content

Research, Translated

Plain-language summaries of real, recent epilepsy research and developments, for patients and families. Every item links to a verifiable source. Nothing here is medical advice; always talk to your own doctor before changing anything. Last updated June 2026.

How to read epilepsy research news (please read first)

  • Peer review matters. The most reliable findings are checked by independent experts and published in medical journals. Press releases and conference talks are real news, but earlier and less complete.
  • Everyone's epilepsy is different. A treatment that helps one person, age, or seizure type may not help another. Many advances apply only to specific conditions.
  • "Experimental" is not "available." Some items below are still in clinical trials and not FDA-approved. We say so clearly.
  • Be wary of miracle-cure headlines. Real progress is usually "fewer seizures" or "a new option for some people," not a cure for all.
  • Your doctor is the expert on you. Use these as conversation starters, not decisions.

A nasal rescue spray is now approved for children as young as 2

Valtoco (diazepam nasal spray) is a medicine a caregiver sprays into the nose to quickly stop a seizure cluster (a burst of seizures different from the person's usual pattern). It was approved only for ages 6 and up; in April 2025 the FDA expanded it to ages 2 to 5, giving younger children a needle-free rescue option at home.

What this could mean for families: for young children with seizure clusters, a possibly simpler, less stressful emergency option. It is not a daily preventive and is not right for every child, ask your doctor whether a nasal rescue plan fits. April 2025. Source: Contemporary Pediatrics

A common seizure pill can now be given as a liquid or feeding tube

Xcopri (cenobamate), a daily medicine for focal seizures in adults, received FDA approval in April 2024 for new ways to take it: the tablet can be crushed into a liquid and swallowed or given through a feeding tube. This is a new way to give the medicine, not a new use or age group.

What this could mean for families: helps people who have trouble swallowing pills still get the medicine. The use is still focal seizures in adults. Never crush a medication without asking your doctor or pharmacist first. April 2024. Source: SK Life Science announcement

Seizure-alert smartwatches: helpful, but they miss many seizures

Wrist devices like the Empatica Embrace2 (FDA-cleared for ages 6+) sense shaking and skin changes to detect convulsive (tonic-clonic) seizures and alert a caregiver. Evidence supports good detection of convulsive seizures and faster help. But the maker is clear that it does not detect non-convulsive seizures (such as absence or many focal seizures) and will not catch every seizure, and no device has been proven to prevent SUDEP.

What this could mean for families: an alert device may add peace of mind and faster response for convulsive seizures, especially at night, but it is a supplement, not a replacement, for care, and it misses many seizure types. Ask your doctor whether one fits and what it can realistically do. Device current as of 2026. Sources: Empatica, Epilepsy Foundation

Lowering SUDEP risk: seizure control and nighttime supervision

SUDEP (Sudden Unexpected Death in Epilepsy) is rare but serious. Recent reviews (Epilepsia 2023; Epilepsy & Behavior 2024) confirm that generalized tonic-clonic seizures are the main risk factor, that taking medication as prescribed and controlling those seizures are the key ways to lower risk, and that nighttime supervision (which alert devices can support) is one recognized measure. Doctors are encouraged to counsel families openly about SUDEP.

What this could mean for families: the most consistent message is that better control of convulsive seizures and not missing doses lower risk. SUDEP is uncommon; ask your doctor to explain your specific risk and what steps make sense. (See our SUDEP overview.) 2023-2024. Sources: Epilepsia review, Epilepsy & Behavior review

Epidiolex (prescription CBD): how it's really used

Epidiolex is a purified, FDA-approved cannabidiol (CBD) medicine. Its approved uses remain Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. A 2024 real-world study found that about 40% of people taking it did not have one of those three diagnoses on record, meaning doctors often prescribe it "off-label" for other seizure types (legal and common, but less studied).

What this could mean for families: prescription Epidiolex is regulated and consistent, unlike over-the-counter CBD products (which are not FDA-approved for seizures and vary in quality). If you're curious about CBD, ask your doctor about the prescription medicine and whether your child's diagnosis is a studied use. 2024. Source: Epilepsy & Behavior Reports (exact figure from the abstract; full text paywalled)

Ketogenic diet: strong new evidence for hard-to-treat childhood epilepsy

A 2025 meta-analysis (Frontiers in Nutrition) pooled 9 randomized trials of the high-fat, low-carb ketogenic diet for children whose epilepsy did not respond to medication. Children on the diet were far more likely to improve, on the order of 7 to 8 times the odds of cutting seizures at least in half versus controls. The authors note few trials measured complete seizure freedom and designs varied, so longer trials are still needed.

What this could mean for families: medical diet therapy is an established option for some children with drug-resistant epilepsy, and this adds to the evidence. It is strict and must be supervised by a medical team (dietitian and neurologist), not done on your own. Ask whether dietary therapy could be appropriate. September 2025. Source: Frontiers in Nutrition (open access)

Precision medicine: an experimental drug aimed at the cause of Dravet syndrome

Zorevunersen is an experimental medicine for Dravet syndrome, a severe genetic epilepsy. Rather than only calming seizures, it targets the genetic root cause by boosting a brain protein (Nav1.1) that these children lack. In December 2024 the FDA granted it "Breakthrough Therapy" status (to speed development) after early studies showed fewer seizures and gains in thinking and behavior. It is not FDA-approved, a larger trial is underway with results expected around 2027.

What this could mean for families: a hopeful direction, treatments designed for a specific genetic cause. But it is experimental, applies only to certain genetic (SCN1A) forms of Dravet, and is years from possible approval. If your child has a genetic epilepsy, ask about genetic testing and whether any clinical trials are relevant. December 2024. Source: Practical Neurology

Brain-stimulation devices: strong long-term data and longer batteries

For drug-resistant epilepsy, small implanted devices can substantially reduce seizures, and the technology keeps improving.

  • Responsive neurostimulation (RNS): a device implanted in the skull detects seizure activity and delivers a gentle pulse to stop it. Long-term study data presented in April 2025 (324 patients) showed the typical patient had 82% fewer seizures at 3 years.
  • Deep brain stimulation (DBS): in January 2024 the FDA approved a rechargeable DBS device (battery rated 15+ years) whose approved uses include epilepsy, meaning fewer surgeries over time to replace it.

What this could mean for families: if medications haven't controlled seizures, ask your doctor about a referral to a comprehensive epilepsy center to discuss device and surgical options. These require specialized evaluation and are not right for everyone. 2024-2025. Sources: NeuroPace RNS data, Medtronic Percept RC

Spotted something out of date, or have research you'd like translated? Tell us via LinkedIn. We summarize from verified sources and link each one; we do not give medical advice.